In the context of the BTK inhibitoribrutinib, sulfamate analogues showed low reactivity with comparablepotency in protein labeling, in vitro, and cellular kinase activityassays and were effective in a mouse model of CLL. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.